Search
Tumor genomics and clinicopathologic features better predict recurrent lung adenocarcinoma (LUAD) following primary resection compared with the TNM classification system, according to a recent study from MSK.
Research led by investigators at Memorial Sloan Kettering Cancer Center has shown that therapeutic cloning, also known as somatic-cell nuclear transfer (SCNT), can be used to treat Parkinson's disease in mice.
Dr. Offodile will serve as MSK’s “futurist,” leading strategy efforts and care transformation initiatives at MSK by continuing to develop the core infrastructure, management systems, and processes for enterprise strategy and business development.
Pexidartinib is the first drug approved specifically to treat tenosynovial giant cell tumor.
Learn how experts at MSK who helped develop CAR T cell therapy to fight cancer are making the treatment stronger, safer, more durable and accessible to more people.
Dinshaw J. Patel, a Member in Sloan Kettering Institute's Structural Biology Program and incumbent of the Abby Rockefeller Mauzé Chair in Experimental Therapeutics, was elected to the National Academy of Sciences at its 146th annual meeting in April.
MSK researchers discover a possible reason why people with kidney cancer respond better to treatments such as immunotherapy if they are obese.
MSK 斯隆的研究人员发现了肾癌患者在肥胖的情况下对免疫疗法等治疗反应更好的一个可能原因。MSK 斯隆的研究人员发现了肾癌患者在肥胖的情况下对免疫疗法等治疗反应更好的一个可能原因。
African American patients with colorectal cancer are less likely to have tumors that respond well to newer treatments such as targeted therapy and immunotherapy.
It can be hard to understand all the various radiation therapy options for prostate cancer. Here, we explain.